RxDoctor Payments Data

Andrew Cash

Internal Medicine · Indiana, PANPI 1790782555

Payments from drug & device makers

$8,013in general payments, 2019–2025

Across 564 payments — averaging $14.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$993
  • Johnson & Johnson$897
  • Novo Nordisk$677
  • Pfizer$622
  • Lilly USA, LLC$593
  • AstraZeneca$534
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$7,90899%
  • Education$1051%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,013 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$135,242
Medicare patients
262
Services billed
1,572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban129$119,369
Trelegy ElliptaFluticasone/Umeclidin/Vilanter79$56,735
JardianceEmpagliflozin47$52,942
OzempicSemaglutide32$45,073
FarxigaDapagliflozin Propanediol35$36,952
XareltoRivaroxaban23$25,363
JanuviaSitagliptin Phosphate15$15,160
TradjentaLinagliptin19$12,354
MyrbetriqMirabegron42$11,283
InvokanaCanagliflozin14$11,187
Breo ElliptaFluticasone/Vilanterol13$9,541
Stiolto RespimatTiotropium Br/Olodaterol Hcl18$8,038
LinzessLinaclotide11$7,019
Pantoprazole Sodium435$6,802
Atorvastatin Calcium340$4,960

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$622$122,191146 claims
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$340$73,33484 claims
GSKTrelegy Ellipta, Breo Ellipta$492$66,27692 claims
Novo NordiskOzempic$677$45,07332 claims
AstraZenecaFarxiga$534$36,95235 claims
Johnson & JohnsonXarelto, Invokana$897$36,55037 claims
MerckJanuvia$293$15,16015 claims
Astellas Pharma US IncMyrbetriq$503$11,28342 claims
AbbVieLinzess, Synthroid$993$10,40878 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Indiana

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →